Is this the groundbreaking drug that could finally put an end to Alzheimer’s symptoms? Scientists are optimistic that they have discovered a new treatment that can ‘turn off’ the gene responsible for causing the disease. The treatment, known as ALN-APP, utilizes a technology called ‘RNA interference’ to prevent the production of toxic proteins in cells. …
A surprising early indicator of Alzheimer’s disease is a loss of smell, according to a new study. The study found that individuals with the APOE e4 gene, the same gene that actor Chris Hemsworth disclosed having two copies of, were more likely to experience a decline in their sense of smell and cognitive function compared …
Researchers made an astounding announcement at a medical conference in Amsterdam last week regarding a new drug called donanemab. This drug has the potential to significantly slow down the progression of Alzheimer’s disease, which is a groundbreaking breakthrough in dementia research. The fact that this news was met with cheers from the audience is a …
A remarkable new Alzheimer’s drug is currently in development and shows potential to surpass its competitors. Early trial findings indicate that remternetug is highly promising in its ability to clear the brain of amyloid, the protein responsible for the debilitating effects of Alzheimer’s disease. While remternetug has yet to receive approval for human use, donanemab …
An interactive map created by MailOnline reveals that up to one in 35 people in certain parts of England have dementia. Charities estimate that approximately 950,000 people across the country are living with this memory-robbing disorder, a number that is expected to increase to 2 million by 2050 as life expectancy rises. Scientists are urging …
Jim Sirois and his wife Sue are living with the challenges of early-onset Alzheimer’s. But their experience has taken a hopeful turn with the introduction of a groundbreaking new drug called donanemab. Unlike previous medications, donanemab has shown promising results in slowing down the progression of Alzheimer’s disease. Patients involved in clinical trials, including Jim …
The Alzheimer’s Association International Conference (AAIC) has released a groundbreaking report revealing the regions in the US most affected by Alzheimer’s disease. This report provides the most detailed analysis to date, estimating rates of the disease at the county level. It shows that seniors on the East Coast and South East are most likely to …
Scientists have cautioned against exaggerated claims that a new drug called Donanemab can significantly slow the progression of Alzheimer’s disease. Eli Lilly, the US pharmaceutical company, recently revealed final trial results suggesting that Donanemab could reduce memory decline by a third. However, critics argue that the drug’s effects may not be noticeable to patients or …
Scientists have found a new drug, called Donanemab, which has the potential to slow down mental decline caused by Alzheimer’s disease by 36%, presenting a promising breakthrough in the fight against the degenerative brain condition. The initial findings, published on May 3, also revealed that Donanemab could halt the reduction in the ability to perform …
Concerns Raised by Senior Doctors Regarding Patient Consent for Alzheimer’s Drug Trials Doctors Express Fear of Dementia Patients’ Lack of Understanding of Drug Trial Risks By Ethan Ennals Updated: 22:33 BST, 15 July 2023 Concerns have been raised by senior doctors regarding Alzheimer’s patients’ potential lack of awareness when signing up for experimental drug trials. …